- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03956940
Analysis of cfDNA in Patients With Hepatocarcinoma and Treated by Sorafenib or Regorafenib (HELP)
A Sorafenib-Regorafenib Sequence Treatment Monitoring Study Using Liquid Biopsy
Study Overview
Detailed Description
Circulating free deoxyribonucleic acid (cfDNA) is increasingly used in oncology with the aiml of early diagnosis of the disease, its therapeutic management and monitoring the evolution of the disease. Numerous publications have shown that the cfDNA concentration is correlated with the pathology of cancer. Larger amounts of cfDNA are detected in metastatic patients or patients with advanced cancer. However, the cfDNA concentrations have not yet shown their clinical interest mainly because of the variations in the same individual during the effort or the moment of collection of the blood sample. The concept of the integrity of cfDNA has also been studied as a biomarker in oncology and seems to show an interesting clinical value. The cfDNA is essentially released by cell apoptosis generating 170 bp fragments, corresponding to the size of a nucleosome. Many studies have shown that the integrity of cfDNA increases with the pathology of cancer. Thus, tumor-derived cfDNA is more fragmented than healthy cells with fragments smaller than the size nucleosome.
To date, no predictive biomarker is available for the management of treatment with Sorafenib which is a targeted therapy with a marketing authorization in first-line treatment of HCC (hepatocellular carcinoma) or second line with Regorafenib, treatment having shown a benefit positive on overall survival in the Resorce study. AFP (alpha-foetoprotein) is the only serum marker available with an inconstant increase in patients with HCC in fact only 30 to 40% of patients have abnormal values. In liver cancer, Ono et al showed that serum cfDNA is positively correlated with a larger tumor size.
This study shows that the rate of tumor cfDNA reflects the progression of the disease. Jiang et al showed that cfDNA derived from HCC is more fragmented than that derived from healthy cells, with fragments smaller than the size nucleosome.
These data demonstrate the potential utility of cfDNA amount and integrity as a biomarker for individualized management of hepatocellular carcinoma.
This new marker is expected to be an effective tool to overcome the lack of specificity of the AFP (alpha foetoprotein) assay in this pathology.
The investigator's team developed an Intplex® test that showed significant discrimination between healthy individuals and cancer patients.
The aim of this trial is to investigate whether quantitative analysis of the total concentration of cfDNA and of the cfDNA integrity index (DII) (Intplex®) may reflect HCC tumor dynamics or response for patients treated by Sorafenib or Regorafenib and if it could be used as a tool for patient management under targeted therapy.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Hérault
-
Montpellier, Hérault, France, 34295
- Hôpital Saint-Eloi
-
-
Isère
-
Grenoble, Isère, France, 38043
- CHU Grenoble - Hôpital Michalon
-
-
Loire-Atlantique
-
Nantes, Loire-Atlantique, France, 44093
- Hôpital Hotel Dieu
-
-
Meurthe Et Moselle
-
Vandœuvre-lès-Nancy, Meurthe Et Moselle, France, 54511
- CHRU Nancy - Hôpital Brabois
-
-
Nord
-
Lille, Nord, France, 59037
- CHRU de Lille - Hôpital Claude Duriez
-
-
Seine-Saint-Denis
-
Clichy, Seine-Saint-Denis, France, 92210
- Hopital Beaujon
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female patients ≥ 18 years of age
- Histological or cytological documentation of hepatocellular carcinoma (HCC) or non-invasive diagnosis of HCC as per American Association for the Study of Liver Diseases (AASLD) criteria in patients with a confirmed diagnosis of cirrhosis
- Patient treated for stage B hepatocellular carcinoma (multifocal disease) or stage C (metastatic disease) according to Barcelona Clinic liver cancer, regardless of treatment line, and that cannot benefit from local treatments such as resection, local ablation, chemoembolization
- At least one uni-dimensional measurable lesion by computed tomography (CT) scan or magnetic resonance imaging (MRI) according to RECIST criteria 1.1 and modified RECIST for HCC
- Liver function status Child-Pugh Class A
- Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 1
Adequate bone marrow, liver and renal function as assessed by the following laboratory tests:
- Hemoglobin > 8.5 g/dL
- Absolute neutrophil count ≥ 1500/mm3
- Platelet count ≥ 60,000/ mm3
- Total bilirubin ≤ 2 mg/dL
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 5 x upper limit of normal (ULN)
- Serum creatinine ≤ 1.5 x Upper limit normal (ULN)
- Lipase ≤ 2 x ULN
- Prothrombin time-international normalized ratio (PT-INR) < 2.3 x ULN and partial thromboplastin time (PTT) < 1.5 x ULN
- Glomerular Filtration Rate (GFR) ≥ 30 mL/min/1.73 m2
- Life expectancy ≥ 3 months
- Women of childbearing potential and men must agree to use adequate contraception
- Patients must be affiliated to a Social Security System
Written informed consent signed
Patients initially treated with Sorafenib, will be switched to Regorafenib if all the above conditions are still met and, in addition:
- Documented progression under treatment with Sorafenib (defined as documented radiological and/or clinical and/or biological progression)
Exclusion Criteria:
- Prior liver transplantation or candidates for liver transplantation
- Hypersensitivity to the active substance or to any of the excipients
- Patients with large esophageal varices at risk of bleeding that are not being treated with conventional medical intervention
- Past or concurrent history of neoplasm other than HCC, except for in situ carcinoma of the cervix uteri and/or non-melanoma skin cancer and superficial bladder tumors. Any cancer curatively treated > 3 years prior to study entry is permitted
- Known history or symptomatic metastatic brain or meningeal tumors
- Major surgical procedure or significant traumatic injury within 28 days before enrollment
- Congestive heart failure New York Heart Association (NYHA) ≥ class 2
- Unstable angina or myocardial infarction within the past 6 months before enrollment
- Cardiac arrhythmias requiring anti-arrhythmic therapy
- Uncontrolled hypertension
- Patients with phaeochromocytoma
- Uncontrolled ascites
- Persistent proteinuria of NCI-CTCAE version 4.0 ≥ Grade 3
- Ongoing infection > Grade 2 according to NCI-CTCAE version 4.0. Hepatitis B is allowed if no active replication is required
- Clinically significant bleeding NCI-CTCAE version 4.0 ≥ Grade 3 within 30 days before enrollment
- Arterial or venous thrombotic or embolic events such as cerebrovascular accident, deep vein thrombosis or pulmonary embolism within 6 months before enrollment
- Any psychological, familial, sociological, geographical or illness or medical condition that could jeopardize the safety of the patient and/or his compliance with the study protocol and follow-up procedure
- Known history of human immunodeficiency virus (HIV) infection
- Seizure disorder requiring medication
- Non-healing wound, ulcer or bone fracture
- Active autoimmune disease (lupus, sclerodermia, rheumatoid arthritis, …)
- Any malabsorption condition
- Breast feeding
- Pregnancy
- High performance sport practice
Patient unable to swallow oral medication
Patients who discontinue sorafenib will not be switched to regorafenib if any of the condition listed above occurs and/or the following criteria are met:
- Prior discontinuation of prior Sorafenib therapy due to Sorafenib-related toxicity
- Unresolved toxicity (Sorafenib) ≥ NCI-CTCAE version 4.0 Grade 2
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intplex test
In vitro diagnostic device
|
Blood sample at baseline, 15 days, 4-8-16 weeks and then every 12 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Detection rate of total circulating free deoxyribonucleic acid (cfDNA) concentration at the baseline.
Time Frame: Baseline
|
Total cfDNA concentration is considered as detected if total cfDNA concentration ≥ 5 ng/mL and not detected if total cfDNA concentration < 5 ng/mL
|
Baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
total circulating free deoxyribonucleic acid (cfDNA) fragmentation index
Time Frame: Baseline
|
Fragmentation of cfDNA
|
Baseline
|
Objective response rate
Time Frame: Approximately 36 months
|
From the date of inclusion to the date of death from any cause
|
Approximately 36 months
|
Disease control rate
Time Frame: Approximately 36 months
|
From the date of inclusion to the date of death from any cause
|
Approximately 36 months
|
Progression-Free Survival
Time Frame: Approximately 36 months
|
The time from the date of start of Sorafenib (Regorafenib respectively) to the date of first documented
|
Approximately 36 months
|
Time-to-progression
Time Frame: Approximately 36 months
|
The time from the date of start of Sorafenib (Regorafenib respectively) to the date of first documented progression ( radiological or clinical)
|
Approximately 36 months
|
Overall Survival
Time Frame: Approximately 36 months
|
The time from the date of start of Sorafenib to the date of documented death from any cause
|
Approximately 36 months
|
Collaborators and Investigators
Investigators
- Study Chair: Eric ASSENAT, MD, Institut Régional du Cancer de Montpellier
Publications and helpful links
General Publications
- Thierry AR, El Messaoudi S, Gahan PB, Anker P, Stroun M. Origins, structures, and functions of circulating DNA in oncology. Cancer Metastasis Rev. 2016 Sep;35(3):347-76. doi: 10.1007/s10555-016-9629-x.
- Duvoux C, Roudot-Thoraval F, Decaens T, Pessione F, Badran H, Piardi T, Francoz C, Compagnon P, Vanlemmens C, Dumortier J, Dharancy S, Gugenheim J, Bernard PH, Adam R, Radenne S, Muscari F, Conti F, Hardwigsen J, Pageaux GP, Chazouilleres O, Salame E, Hilleret MN, Lebray P, Abergel A, Debette-Gratien M, Kluger MD, Mallat A, Azoulay D, Cherqui D; Liver Transplantation French Study Group. Liver transplantation for hepatocellular carcinoma: a model including alpha-fetoprotein improves the performance of Milan criteria. Gastroenterology. 2012 Oct;143(4):986-94.e3; quiz e14-5. doi: 10.1053/j.gastro.2012.05.052. Epub 2012 Jun 29.
- Thierry AR, Mouliere F, El Messaoudi S, Mollevi C, Lopez-Crapez E, Rolet F, Gillet B, Gongora C, Dechelotte P, Robert B, Del Rio M, Lamy PJ, Bibeau F, Nouaille M, Loriot V, Jarrousse AS, Molina F, Mathonnet M, Pezet D, Ychou M. Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. Nat Med. 2014 Apr;20(4):430-5. doi: 10.1038/nm.3511. Epub 2014 Mar 23.
- Mouliere F, El Messaoudi S, Pang D, Dritschilo A, Thierry AR. Multi-marker analysis of circulating cell-free DNA toward personalized medicine for colorectal cancer. Mol Oncol. 2014 Jul;8(5):927-41. doi: 10.1016/j.molonc.2014.02.005. Epub 2014 Mar 24.
- Gupta S, Bent S, Kohlwes J. Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis. Ann Intern Med. 2003 Jul 1;139(1):46-50. doi: 10.7326/0003-4819-139-1-200307010-00012.
- Riaz A, Ryu RK, Kulik LM, Mulcahy MF, Lewandowski RJ, Minocha J, Ibrahim SM, Sato KT, Baker T, Miller FH, Newman S, Omary R, Abecassis M, Benson AB 3rd, Salem R. Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival. J Clin Oncol. 2009 Dec 1;27(34):5734-42. doi: 10.1200/JCO.2009.23.1282. Epub 2009 Oct 5.
- Chan SL, Mo FK, Johnson PJ, Hui EP, Ma BB, Ho WM, Lam KC, Chan AT, Mok TS, Yeo W. New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. J Clin Oncol. 2009 Jan 20;27(3):446-52. doi: 10.1200/JCO.2008.18.8151. Epub 2008 Dec 8.
- Personeni N, Bozzarelli S, Pressiani T, Rimassa L, Tronconi MC, Sclafani F, Carnaghi C, Pedicini V, Giordano L, Santoro A. Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma. J Hepatol. 2012 Jul;57(1):101-7. doi: 10.1016/j.jhep.2012.02.016. Epub 2012 Mar 10.
- Yamashita T, Forgues M, Wang W, Kim JW, Ye Q, Jia H, Budhu A, Zanetti KA, Chen Y, Qin LX, Tang ZY, Wang XW. EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res. 2008 Mar 1;68(5):1451-61. doi: 10.1158/0008-5472.CAN-07-6013.
- Sozzi G, Conte D, Mariani L, Lo Vullo S, Roz L, Lombardo C, Pierotti MA, Tavecchio L. Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients. Cancer Res. 2001 Jun 15;61(12):4675-8.
- Ono A, Fujimoto A, Yamamoto Y, Akamatsu S, Hiraga N, Imamura M, Kawaoka T, Tsuge M, Abe H, Hayes CN, Miki D, Furuta M, Tsunoda T, Miyano S, Kubo M, Aikata H, Ochi H, Kawakami YI, Arihiro K, Ohdan H, Nakagawa H, Chayama K. Circulating Tumor DNA Analysis for Liver Cancers and Its Usefulness as a Liquid Biopsy. Cell Mol Gastroenterol Hepatol. 2015 Jun 17;1(5):516-534. doi: 10.1016/j.jcmgh.2015.06.009. eCollection 2015 Sep.
- Jiang P, Chan CW, Chan KC, Cheng SH, Wong J, Wong VW, Wong GL, Chan SL, Mok TS, Chan HL, Lai PB, Chiu RW, Lo YM. Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients. Proc Natl Acad Sci U S A. 2015 Mar 17;112(11):E1317-25. doi: 10.1073/pnas.1500076112. Epub 2015 Feb 2.
- Diaz LA Jr, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol. 2014 Feb 20;32(6):579-86. doi: 10.1200/JCO.2012.45.2011. Epub 2014 Jan 21.
- El Messaoudi S, Mouliere F, Du Manoir S, Bascoul-Mollevi C, Gillet B, Nouaille M, Fiess C, Crapez E, Bibeau F, Theillet C, Mazard T, Pezet D, Mathonnet M, Ychou M, Thierry AR. Circulating DNA as a Strong Multimarker Prognostic Tool for Metastatic Colorectal Cancer Patient Management Care. Clin Cancer Res. 2016 Jun 15;22(12):3067-77. doi: 10.1158/1078-0432.CCR-15-0297. Epub 2016 Feb 4.
- Zonta E, Nizard P, Taly V. Assessment of DNA Integrity, Applications for Cancer Research. Adv Clin Chem. 2015;70:197-246. doi: 10.1016/bs.acc.2015.03.002. Epub 2015 Apr 11.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2018-A02911-54
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatocarcinoma
-
Hospital DonostiaINSTITUTO BIODONOSTIACompletedAdvanced HepatocarcinomaSpain
-
Istituto Clinico HumanitasCompletedHepatocarcinomaItaly
-
Istituto Clinico HumanitasRecruiting
-
IHU StrasbourgCompleted
-
Xiangya Hospital of Central South UniversityRecruitingHepatocellular CarcinomaChina
-
Qidong Gaitianli Medicines Co., LtdHuazhong University of Science and TechnologyTerminated
-
Mauna Kea TechnologiesUnknownHepatocarcinoma | Hepatic Tumor | Hepatic MetastasisFrance
-
Stefano ColagrandeUniversity of Trieste; University of Rome Tor Vergata; Azienda Socio Sanitaria... and other collaboratorsCompletedLiver Metastases | HepatocarcinomaItaly
-
Fudan UniversityRecruiting
-
Yue HanRecruiting
Clinical Trials on Intplex test
-
Institut du Cancer de Montpellier - Val d'AurelleActive, not recruiting
-
Recep Tayyip Erdogan University Training and Research...Completed
-
Groupe Hospitalier Mutualiste de GrenobleFondation de l'AvenirCompleted
-
Yonsei UniversityCompletedPostprandial Hyperglycemia
-
University of FloridaCompletedParkinson Disease (PD)United States
-
Guven Health GroupCompletedAthletic Performance | Physical Fitness | Handball Players | Cross-sectional StudiesTurkey
-
French National Agency for Research on AIDS and...Completed
-
Clinical Nutrition Research Centre, SingaporeCompleted
-
M.D. Anderson Cancer CenterUnknownLung CancerUnited States